← Back to patent-cliff list
CAS 10310-21-1
6-chloro-9H-purin-2-amine
Codes: NELA-001, AT-527-003
Application context (from source-drug indications)
T-lymphoblastic lymphoma/leukaemiaNelarabineSézary syndromeNelarabineMarginal zone B-cell lymphomaNelarabineAdult T-cell leukaemia/lymphomaNelarabineWaldenström macroglobulinaemiaNelarabineLymphomaNelarabineHepatitis CBemnifosbuvirCOVID-19BemnifosbuvirLiver cirrhosisBemnifosbuvirChronic hepatitis CBemnifosbuvirHepatic function declineBemnifosbuvirRenal impairmentBemnifosbuvir
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Nelarabine | Tier C — Watch / trade | - |
| Bemnifosbuvir | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
6-chloro-9H-purin-2-amine→6-methoxy-9H-purin-2-amine→(R)-3-((2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridine-2,6(1H,3H)-dione
((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl benzoate→((2R,3R,4R,5R)-3-(benzoyloxy)-5-bromo-4-fluoro-4-methyltetrahydrofuran-2-yl)methyl benzoate→6-chloro-9H-purin-2-amine→(2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-((benzoyloxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate→(2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol→isopropyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-D-alaninate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.